Applied BioCode (TPE:6598) EBIT: NT$-199.5 Mil (TTM As of Dec. 2025)


TPE:6598 Applied BioCode Corp TPE:6598
74 GF Score
Price NT$22.90
GF Value NT$23.33
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Applied BioCode EBIT?

Applied BioCode TPE:6598 -1.29% 74 EBIT is NT$-199.5 Mil as of Dec. 2025. GuruFocus rates TPE:6598 with a GF Score™ of 74/100 and a GF Value™ of NT$23.33 (Fairly Valued). The stock has 6 warning signs investors should review.

Applied BioCode's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was NT$-63.4 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-199.5 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Applied BioCode's annualized ROC % for the quarter that ended in Dec. 2025 was -74.41%. Applied BioCode's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -79.21%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Applied BioCode's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -10.82%.


Applied BioCode  (TPE:6598) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Applied BioCode's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-274.58 * ( 1 - 0% )/( (357.858 + 380.169)/ 2 )
=-274.58/369.0135
=-74.41 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1030.798 - 54.777 - ( 618.163 - max(0, 110.294 - 877.428+618.163))
=357.858

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1012.704 - 62.947 - ( 569.588 - max(0, 126.546 - 858.461+569.588))
=380.169

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Applied BioCode's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-253.596/( ( (143.888 + max(168.816, 0)) + (144.529 + max(183.12, 0)) )/ 2 )
=-253.596/( ( 312.704 + 327.649 )/ 2 )
=-253.596/320.1765
=-79.21 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(83.09 + 170.031 + 6.144) - (54.777 + 0 + 35.672)
=168.816

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(121.982 + 156.294 + 10.597) - (62.947 + 0 + 42.806)
=183.12

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Applied BioCode's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-199.534/1844.526
=-10.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Applied BioCode EBIT Related Terms


Applied BioCode EBIT Historical Data

* Premium members only.

The historical data trend for Applied BioCode's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Applied BioCode EBIT Chart

Applied BioCode Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -162.31 -181.93 -161.28 -259.35 -199.53

Applied BioCode Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -70.57 -35.47 -67.35 -33.32 -63.40

TPE:6598 vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Applied BioCode's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Applied BioCode EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Applied BioCode's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Applied BioCode's EV-to-EBIT falls into.


TPE:6598
74GF Score
Applied BioCode Corp TPE:6598
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Applied BioCode EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-199.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$-199.5 Mil mean?
Applied BioCode (TPE:6598) has a EBIT of NT$-199.5 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Applied BioCode.
Is Applied BioCode's EBIT too high?
Applied BioCode's current EBIT is NT$-199.5 Mil. Overall, Applied BioCode has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Applied BioCode's EBIT compare to ABT and SYK?
Applied BioCode's EBIT of NT$-199.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Applied BioCode. Applied BioCode's current EBIT is NT$-199.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Applied BioCode stock overvalued right now?
Based on GuruFocus' analysis, Applied BioCode (TPE:6598) is currently considered Fairly Valued. The stock's GF Value™ is NT$23.33, compared to a current price of NT$22.90 — trading 1.8% below its estimated fair value. The current EBIT is NT$-199.5 Mil. Applied BioCode's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Applied BioCode (TPE:6598), the current EBIT is NT$-199.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Applied BioCode (TPE:6598) Overvalued in 2026?

Based on GuruFocus' analysis, Applied BioCode stock appears to be undervalued. The current stock price of NT$22.90 is trading 1.8% below its estimated GF Value™ of NT$23.33. GuruFocus considers Applied BioCode to be Fairly Valued.

Key valuation signals for TPE:6598:

  • EBIT: NT$-199.5 Mil
  • GF Value™: NT$23.33 vs. price of NT$22.90 (1.8% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the TPE:6598 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Applied BioCode Business Description

Address 12130 Mora Dr., Unit 2, Santa Fe Springs, CA, USA, 90670
Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.
74GF Score

Get the complete analysis for TPE:6598

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$22.90
Price
NT$23.33
GF Value